Influencing Factors and Survival Analysis of Late Readmission after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction
DOI:
https://doi.org/10.59958/hsf.7475Keywords:
percutaneous coronary intervention, acute myocardial infarction, late readmission, survival analysisAbstract
Objective: This study aimed to explore the influencing factors analysis of late readmission after patients with acute myocardial infarction received percutaneous coronary intervention (PCI). Methods: A total of 368 patients with acute myocardial infarction who received PCI treatment in West China Hospital, Sichuan University/West China School of Nursing, Sichuan University from January 2018, to January 2021, were selected for the study. Among them, 110 subjects were excluded, and 258 subjects were finally included, of which 124 were readmitted and 134 were not readmitted. The baseline data and clinical characteristics of the patients were collected, and the influencing factors of readmission were analyzed by logistic regression analysis. The readmitted patients were followed up for 12 months. The Kaplan–Meier method was used to analyze the survival of patients with delayed readmitted and calculate the survival rate. Results: Significant differences were found between readmitted patients and non-readmitted patients in terms of age, chronic obstructive pulmonary disease (COPD), history of early coronary heart disease, history of hypertension, history of oral anticoagulant drugs, and left ventricle ejection fraction (LVEF, p < 0.05). No significant differences were observed in gender, body mass index, family history of acute myocardial infarction, history of chronic kidney disease, history of diabetes, history of smoking, history of drinking, and the number of implanted stents and diseased vessels (p > 0.05). Binary logistic regression analysis showed that age, COPD, history of premature coronary heart disease, history of oral anticoagulant drugs, and LVEF were important influencing factors of delayed readmission after PCI (all p < 0.05). Follow-up results showed that 125 patients survived and nine died among the delayed non-readmission patients after PCI. Among the patients with delayed readmission, 95 survived and 29 died. Kaplan–Meier survival analysis showed that the survival time of patients with delayed non-readmission was longer than that of patients with delayed readmission, and the difference was statistically significant (χ2 = 17.696, p < 0.001). Conclusion: Age, COPD, history of oral anticoagulant drugs, and LVEF are important influencing factors of delayed readmission after PCI, and the survival time of patients with delayed non-readmission is longer than that of patients with delayed readmission.
References
Kubota A, Frangogiannis NG. Macrophages in myocardial infarction. American Journal of Physiology. Cell Physiology. 2022; 323: C1304–C1324.
Gardiner R, Muradagha H, Kiernan TJ. Intravascular lithotripsy during percutaneous coronary intervention: current concepts. Expert Review of Cardiovascular Therapy. 2022; 20: 323–338.
Hoebart C, Kiss A, Pilz PM, Szabo PL, Podesser BK, Fischer MJM, et al. TRPA1 as Target in Myocardial Infarction. International Journal of Molecular Sciences. 2023; 24: 2516.
Shawon MSR, Odutola M, Falster MO, Jorm LR. Patient and hospital factors associated with 30-day readmissions after coronary artery bypass graft (CABG) surgery: a systematic review and meta-analysis. Journal of Cardiothoracic Surgery. 2021; 16: 172.
Furtado RHM, Fagundes AA, Jr, Oyama K, Zelniker TA, Tang M, Kuder JF, et al. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circulation. Cardiovascular Interventions. 2022; 15: e011382.
Ahmad M, Mehta P, Reddivari AKR, Mungee S. Percutaneous Coronary Intervention. 2023. In: StatPearls. Treasure Island, FL: StatPearls Publishing. Available at: http://pubmed.ncbi.nlm.nih.gov/32310583/ (Accessed: 8 January 2024).
Zhang N, Aiyasiding X, Li WJ, Liao HH, Tang QZ. Neutrophil degranulation and myocardial infarction. Cell Communication and Signaling. 2022; 20: 50.
Holmes DR Jr, Barsness GW. Percutaneous Coronary Intervention for Chronic Total Occlusions. Circulation. Cardiovascular Interventions. 2019; 12: e008321.
Lizzo JM, Chowdhury YS. Posterior Myocardial Infarction. 2023. In: StatPearls. Treasure Island, FL: StatPearls Publishing. Available at: http://pubmed.ncbi.nlm.nih.gov/31985961/ (Accessed: 6 January 2024).
Silverio A, De Luca G, Sarno G, Galasso G. Editorial: Advances in Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine. 2022; 9: 914487.
Sanz-Sánchez J, Mashayekhi K, Agostoni P, Egred M, Avran A, Kalyanasundaram A, et al. Device entrapment during percutaneous coronary intervention. Catheterization and Cardiovascular Interventions. 2022; 99: 1766–1777.
Mechanic OJ, Gavin M, Grossman SA. Acute Myocardial Infarction. 2023. In: StatPearls. Treasure Island, FL: StatPearls Publishing. Available at: http://pubmed.ncbi.nlm.nih.gov/29083808/ (Accessed: 6 January 2024).
Lam L, Ahn HJ, Okajima K, Schoenman K, Seto TB, Shohet RV, et al. Gender Differences in the Rate of 30-Day Readmissions after Percutaneous Coronary Intervention for Acute Coronary Syndrome. Women’s Health Issues. 2019; 29: 17–22.
Saleh M, Ambrose JA. Understanding myocardial infarction. F1000Research. 2018; 7: F1000 Faculty Rev-1378.
Zhao L, Chen M, Yang X. Serpina3 in myocardial infarction. International Journal of Cardiology. 2020; 306: 8.
Geng N, Ren L, Xu L, Zou D, Pang W. Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders. 2021; 21: 488.
Freites A, Hernando L, Salinas P, Cánovas E, de la Rosa A, Alonso J, et al. Incidence and prognosis of late readmission after percutaneous coronary intervention. Cardiology Journal. 2023; 30: 696–704.
Guo FY, Meng Fan H, Huang Sheng N, Fu Zhen Y..Analysis of reasons for cardiac unplanned readmission in patients undergoing percutaneous coronary intervention one year after surgery. Chinese Cardiovascular Disease Research. 2022; 20: 14–19.
Yao Y, Zhu P, Xu N, Jiang L, Tang XF, Song Y, et al. Effects of chronic obstructive pulmonary disease on long-term prognosis of patients with coronary heart disease post-percutaneous coronary intervention. Journal of Geriatric Cardiology. 2022; 19: 428–434.
Tang M, Long Y, Liu S, Yue X, Shi T. Prevalence of Cardiovascular Events and Their Risk Factors in Patients With Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea Overlap Syndrome. Frontiers in Cardiovascular Medicine. 2021; 8: 694806.
Vidula MK, McCarthy CP, Butala NM, Kennedy KF, Wasfy JH, Yeh RW, et al. Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLoS ONE. 2018; 13: e0205457.
Perelshtein Brezinov O, Klempfner R, Zekry SB, Goldenberg I, Kuperstein R. Prognostic value of ejection fraction in patients admitted with acute coronary syndrome: A real world study. Medicine. 2017; 96: e6226.
Zhang Y, Shi F. Predictive Value of the Lipoprotein(a) to Prealbumin Ratio and of the NT-proBNP to LVEF Ratio for Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. The Heart Surgery Forum. 2023; 26: E470–E477.
